share_log

基石藥業-B：截至二零二三年十二月三十一日止月份之股份發行人的證券變動月報表

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 5 05:41
Summary by Moomoo AI
基石藥業於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元，本月無變動。此外，公司的股份期權計劃中，首次公開發售前激勵計劃及首次公開發售後僱員持股計劃的股份期權數目有所變動。截至本月底，首次公開發售前激勵計劃的股份期權數目由5,050,406減少至4,989,538，而首次公開發售後僱員持股計劃的股份期權數目由76,284,801減少至73,147,494。本月內因行使期權所得資金總額為26,125.12港元。公司確認，所有證券發行均已獲董事會授權批准，並符合相關上市規則要求。
基石藥業於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元，本月無變動。此外，公司的股份期權計劃中，首次公開發售前激勵計劃及首次公開發售後僱員持股計劃的股份期權數目有所變動。截至本月底，首次公開發售前激勵計劃的股份期權數目由5,050,406減少至4,989,538，而首次公開發售後僱員持股計劃的股份期權數目由76,284,801減少至73,147,494。本月內因行使期權所得資金總額為26,125.12港元。公司確認，所有證券發行均已獲董事會授權批准，並符合相關上市規則要求。
Keystone Pharmaceuticals filed with Hong Kong Trading and Clearing Limited on January 5, 2024 the Monthly Securities Change Report for the year ended December 31, 2023. The report showed that the company's regulated/registered share capital remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, unchanged this month. In addition, the number of share options in the company's stock option plans for the pre-IPO incentive plan and the employee share holding plan after the initial public offering has changed. As of the end of this month, the number of share options under the Initial Public Offering Incentive Plan decreased from 5,050,406 to 4,989,538, and the number of share options for the employee holding plan after the IPO decreased from 76,284,801 to 73,147,494. The total amount of capital received from the exercise of options during the month was HK$26,125.12. The Company confirms that all issuance of securities has been authorized by the Board of Directors and meets the requirements of the relevant Listing Rules.
Keystone Pharmaceuticals filed with Hong Kong Trading and Clearing Limited on January 5, 2024 the Monthly Securities Change Report for the year ended December 31, 2023. The report showed that the company's regulated/registered share capital remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, unchanged this month. In addition, the number of share options in the company's stock option plans for the pre-IPO incentive plan and the employee share holding plan after the initial public offering has changed. As of the end of this month, the number of share options under the Initial Public Offering Incentive Plan decreased from 5,050,406 to 4,989,538, and the number of share options for the employee holding plan after the IPO decreased from 76,284,801 to 73,147,494. The total amount of capital received from the exercise of options during the month was HK$26,125.12. The Company confirms that all issuance of securities has been authorized by the Board of Directors and meets the requirements of the relevant Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more